Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease
- PMID: 18992746
- DOI: 10.1053/j.gastro.2008.09.013
Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease
Abstract
Background & aims: Nonalcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in children and adolescents in industrialized countries. It is important to accurately determine the stage of fibrosis in these patients. The enhanced liver fibrosis (ELF) test has been validated for staging liver fibrosis in adult patients with chronic liver diseases, including NAFLD. We investigated the performance of this test in assessing liver fibrosis in children and adolescents with NAFLD, identified by biopsy.
Methods: The ELF test was performed on a panel of serum samples collected from 112 consecutive subjects that were likely to have NAFLD (64 male, mean age of 13.8+/-3.3). A previously described and validated algorithm was used to analyze the data on hyaluronic acid (HA), amino-terminal propeptide of type III collagen (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1) levels.
Results: In pediatric patients with NAFLD, the ELF test predicted liver fibrosis stage with a high degree of sensitivity and specificity; results were superior to those reported for adults. The area under receiver operating characteristic curves/best possible ELF test cut-off values for the prediction of "any" (>or= stage 1), moderate-perisinusoidal (>or= stage 1b), moderate-portal/periportal (>or= stage 1c), significant (>or= stage 2), or advanced (>or= stage 3) fibrosis were 0.92/9.28, 0.92/9.33, 0.90/9.54, 0.98/10.18 and 0.99/10.51, respectively.
Conclusions: The ELF test can be used to accurately assess the level of liver fibrosis in pediatric patients with NAFLD. This information is important for identifying patients with progressive fibrosis that require further histopathological analysis or therapeutic follow-up.
Similar articles
-
The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.J Hepatol. 2013 Aug;59(2):236-42. doi: 10.1016/j.jhep.2013.03.016. Epub 2013 Mar 21. J Hepatol. 2013. PMID: 23523583
-
Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.Acta Biochim Pol. 2011;58(4):563-6. Epub 2011 Dec 3. Acta Biochim Pol. 2011. PMID: 22140659
-
Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.Obes Surg. 2017 Sep;27(9):2347-2353. doi: 10.1007/s11695-017-2606-9. Obes Surg. 2017. PMID: 28229316 Clinical Trial.
-
Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases.Aliment Pharmacol Ther. 2023 Apr;57(7):750-762. doi: 10.1111/apt.17385. Epub 2023 Jan 17. Aliment Pharmacol Ther. 2023. PMID: 36650720 Review.
-
[Possibility of Using ELF Score as Index for Hepatic Fibrosis Evaluation].Rinsho Byori. 2015 Jan;63(1):78-83. Rinsho Byori. 2015. PMID: 26524882 Review. Japanese.
Cited by
-
Screening strategy for non-alcoholic fatty liver disease.Clin Mol Hepatol. 2023 Feb;29(Suppl):S103-S122. doi: 10.3350/cmh.2022.0336. Epub 2022 Nov 30. Clin Mol Hepatol. 2023. PMID: 36447420 Free PMC article. Review.
-
Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease.World J Gastroenterol. 2012 Apr 7;18(13):1525-30. doi: 10.3748/wjg.v18.i13.1525. World J Gastroenterol. 2012. PMID: 22509085 Free PMC article.
-
Rapid progression of NASH in childhood.J Pediatr Gastroenterol Nutr. 2010 Apr;50(4):453-6. doi: 10.1097/MPG.0b013e3181a9387b. J Pediatr Gastroenterol Nutr. 2010. PMID: 20179647 Free PMC article. No abstract available.
-
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis.Diabetes Metab J. 2019 Feb;43(1):31-45. doi: 10.4093/dmj.2019.0011. Diabetes Metab J. 2019. PMID: 30793550 Free PMC article. Review.
-
Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C.Hepatol Res. 2019 Jul;49(7):731-742. doi: 10.1111/hepr.13333. Epub 2019 May 17. Hepatol Res. 2019. PMID: 30892804 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous